217 related articles for article (PubMed ID: 31784538)
21. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
[TBL] [Abstract][Full Text] [Related]
22. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
Wilhelmson AS; Porse BT
Br J Haematol; 2020 Aug; 190(4):495-507. PubMed ID: 32086816
[TBL] [Abstract][Full Text] [Related]
23. Mutations in the bZip region of the CEBPA gene: A novel prognostic factor in patients with acute myeloid leukemia.
Rivera JC; Nuñez D; Millar E; Ramirez K; Chandía M; Aguayo C
Int J Lab Hematol; 2023 Dec; 45(6):833-838. PubMed ID: 37621152
[TBL] [Abstract][Full Text] [Related]
24. Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia.
Wang T; Hua H; Wang Z; Wang B; Cao L; Qin W; Wu P; Cai X; Chao H; Lu X
Hematology; 2022 Dec; 27(1):994-1002. PubMed ID: 36066283
[TBL] [Abstract][Full Text] [Related]
25. The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
Wei H; Zhou C; Liu B; Lin D; Li Y; Wei S; Gong B; Zhang G; Liu K; Gong X; Fang Q; Liu Y; Qiu S; Gu R; Song Z; Chen J; Yang M; Zhang J; Jin J; Wang Y; Mi Y; Wang J
Br J Haematol; 2022 May; 197(4):442-451. PubMed ID: 35274287
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
[TBL] [Abstract][Full Text] [Related]
27. Role of CSF3R mutations in the pathomechanism of congenital neutropenia and secondary acute myeloid leukemia.
Klimiankou M; Mellor-Heineke S; Zeidler C; Welte K; Skokowa J
Ann N Y Acad Sci; 2016 Apr; 1370(1):119-25. PubMed ID: 27270496
[TBL] [Abstract][Full Text] [Related]
28. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
31. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
Ahmad F; Rajput S; Mandava S; Das BR
Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
[TBL] [Abstract][Full Text] [Related]
32. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.
Jakobsen JS; Laursen LG; Schuster MB; Pundhir S; Schoof E; Ge Y; d'Altri T; Vitting-Seerup K; Rapin N; Gentil C; Jendholm J; Theilgaard-Mönch K; Reckzeh K; Bullinger L; Döhner K; Hokland P; Fitzgibbon J; Porse BT
Sci Adv; 2019 Jul; 5(7):eaaw4304. PubMed ID: 31309149
[TBL] [Abstract][Full Text] [Related]
33. Familial CEBPA-mutated acute myeloid leukemia.
Tawana K; Rio-Machin A; Preudhomme C; Fitzgibbon J
Semin Hematol; 2017 Apr; 54(2):87-93. PubMed ID: 28637622
[TBL] [Abstract][Full Text] [Related]
34. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
[TBL] [Abstract][Full Text] [Related]
35. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
[TBL] [Abstract][Full Text] [Related]
36.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
37. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.
Kuo YY; Hou HA; Chen YK; Li LY; Chen PH; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Chou WC; Liu CY; Tang JL; Yao M; Tien HF
Haematologica; 2014 Dec; 99(12):1799-807. PubMed ID: 25193961
[TBL] [Abstract][Full Text] [Related]
38. Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.
Volpe G; Cauchy P; Walton DS; Ward C; Blakemore D; Bayley R; Clarke ML; Schmidt L; Nerlov C; Garcia P; Dumon S; Grebien F; Frampton J
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877232
[TBL] [Abstract][Full Text] [Related]
39. Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.
Guo H; Ma O; Speck NA; Friedman AD
Blood; 2012 May; 119(19):4408-18. PubMed ID: 22451420
[TBL] [Abstract][Full Text] [Related]
40. In Vivo Deletion of the Cebpa +37 kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis.
Guo H; Cooper S; Friedman AD
PLoS One; 2016; 11(3):e0150809. PubMed ID: 26937964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]